Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolys BioPharma, Inc. (4588) AI Stock Analysis

1 Followers
JP:4588

Oncolys BioPharma, Inc.

(TSE/TYO:4588)

Select Model
Rating:50Neutral
Price Target:JPY 7,620.00â–²(0.00% Upside)
Action:reiterated
Date:09/19/26

The score is held down primarily by weak financial performance (collapsed revenue, large ongoing losses, and heavy cash burn), with valuation also constrained by negative earnings and no dividend data. Strong technical momentum lifts the score, but overbought signals suggest elevated near-term volatility and pullback risk.

Positive Factors
Specialized oncology biotechnology platformA focused oncology and serious-disease pipeline gives Oncolys a specialized development platform spanning novel biologics and virology-based approaches. Its ability to advance candidates through preclinical and clinical stages, while pursuing partnerships, provides multiple routes to build future commercial value.
Negative Factors
Severe revenue deteriorationThe sustained collapse in revenue shows that the company currently lacks a reliable commercial earnings base. Revenue has remained near its 2024 level after the earlier decline, increasing dependence on successful development milestones or commercialization opportunities to restore durable top-line growth.

Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)

-200%0%200%400%600%800%JP:4588+649.26%EWJ+14.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 221.10B
Dividend Yield
―
Average Volume (3M)
1.76M
Price to Earnings (P/E)
-138.2
Beta (1Y)
1.96
Revenue Growth
1748.97%
EPS Growth
35.11%
Country
Japan
Employees
42
Sector
General
Sector Strength
55
Industry
Biotechnology

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the Unit...

How the Company Makes Money

Detailed, company-specific revenue breakdown (e.g., product sales by drug, recurring service revenue, or disclosed milestone/royalty structures) is not available in the information provided here; therefore, this data point is null.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Income Statement and Cash Flow are very weak: revenue has fallen sharply from 2022 levels and the company continues to post large operating and net losses with heavy, persistent cash burn and negative free cash flow. The Balance Sheet is comparatively healthier with modest leverage and an expanded equity base, but ongoing losses raise risk of future value erosion and financing needs.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

21Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue28.55M28.55M31.38M63.04M976.18M642.49M
Gross Profit28.30M28.30M31.38M30.61M338.49M198.80M
EBITDA-2.05B-2.05B-1.68B-1.93B-1.14B-1.60B
Net Income-2.06B-2.06B-1.68B-1.94B-1.15B-1.62B
Balance Sheet
Total Assets4.56B4.56B3.20B2.04B2.65B4.29B
Cash, Cash Equivalents and Short-Term Investments3.72B3.72B2.41B1.53B1.71B3.45B
Total Debt320.02M320.02M324.64M315.17M393.66M503.47M
Total Liabilities555.91M555.91M446.65M566.50M491.69M697.88M
Stockholders Equity4.00B4.00B2.75B1.47B2.16B3.59B
Cash Flow
Free Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Operating Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Investing Cash Flow0-7.58M-4.71M-5.39M20.12M-942.00K
Financing Cash Flow03.22B2.88B1.14B-113.83M3.09B

Oncolys BioPharma, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price7620.00

Price Trends

50DMA6312.10Positive
100DMA4643.25Positive
200DMA3580.01Positive

Market Momentum

MACD547.04Negative
RSI55.94Neutral
STOCH69.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 7620.00 is above the 20-day moving average (MA) of 7200.00, above the 50-day MA of 6312.10, and above the 200-day MA of 3580.01, indicating a bullish trend. The MACD of 547.04 indicates Negative momentum. The RSI at 55.94 is Neutral, neither overbought nor oversold. The STOCH value of 69.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4588 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4588JP:458850NeutralJPY 225.09B-138.17――1748.97%35.11%
JP:4583JP:458349NeutralJPY 6.14B-6.03――-13.40%7.50%
JP:4587JP:458748NeutralJPY 145.66B-49.95-5.85%―14.25%50.07%
JP:4564JP:456440UnderperformJPY 6.12B-6.52-42.81%―-25.56%17.01%
JP:4575JP:457539UnderperformJPY 13.64B-9.80―――-12.48%

* General Sector Average

Performance Comparison

0%200%400%600%JP:4588JP:4587JP:4564JP:4575JP:4583Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4588 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4588Oncolys BioPharma, Inc.7620.006640.00677.55%
JP:4587Peptidream 1122.00-540.00-32.49%
JP:4564OncoTherapy Science, Inc.15.00-7.00-31.82%
JP:4575CanBas Co., Ltd.690.00-98.00-12.44%
JP:4583Chiome Bioscience Inc.75.00-50.00-40.00%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Higher Sales and Narrower Nine-Month Loss

Nov 6, 2026

Oncolys BioPharma reported net sales of ¥527 million for the nine months ended September 30, 2026, up from ¥28 million a year earlier. Operating loss narrowed to ¥1.104 billion from ¥1.571 billion, while net loss improved to ¥1.115 billion from ¥1.61...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026